Variant position: 61 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 189 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human RKQVVIDGETCLLDILDTAG QEEYSAMRDQYMRTGEGFLCV
Mouse RKQVVIDGETCLLDILDTAG QEEYSAMRDQYMRTGEGFLCV
Rat RKQVVIDGETCLLDILDTAG QEEYSAMRDQYMRTGEGFLCV
Chicken RKQVVIDGETCLLDILDTAG QEEYSAMRDQYMRTGEGFLCV
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 186 GTPase HRas
2 – 186 GTPase HRas, N-terminally processed
59 – 59 A -> T. Loss of GTPase activity and creation of an autophosphorylation site.
61 – 61 Q -> I. Moderately increased transformation of cultured cell lines.
61 – 61 Q -> V. Strongly increased transformation of cultured cell lines.
60 – 63
Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf.
Buhrman G.; Wink G.; Mattos C.;
Cited for: X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP ANALOG; CHARACTERIZATION OF VARIANTS LEU-61 AND LYS-61; MUTAGENESIS OF GLN-61;
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Nikiforova M.N.; Lynch R.A.; Biddinger P.W.; Alexander E.K.; Dorn G.W. II; Tallini G.; Kroll T.G.; Nikiforov Y.E.;
J. Clin. Endocrinol. Metab. 88:2318-2326(2003)
Cited for: INVOLVEMENT IN NMTC2; VARIANT NMTC2 LYS-61;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.